15th - BIO...15th EV ANNUENT A L February 11-12, 2013 The Waldorf Astoria New York -2-Now in its...
Transcript of 15th - BIO...15th EV ANNUENT A L February 11-12, 2013 The Waldorf Astoria New York -2-Now in its...
-2-
Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
Top 10 Reasons to attend
Present your company story to an audience of targeted investors.
Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry.
Evaluate fresh investment opportunities including compatible, complementary and competitive companies.
Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.
Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013.
Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event.
Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences.
Get the pulse on the current and proposed investment trends in biotechnology.
Network with peers, investors and potential partners attending the conference.
It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
12
3
4
5
6
7
8
9
10
-3-
Tom Brakel, MDPortfolio Manager, Federated Kaufmann Funds
Advisory Committee
John ChambersManaging Director & Head of Healthcare Investment Banking, Roth Capital Partners
Michael Gilman, PhD Senior Vice President Early-Stage Programs, Biogen Idec
Peter Kolchinksky, PhDManaging Partner, RA Capital Management, LLC
Oleg NodelmanFounder & Managing Director, EcoR1 Capital
Joel SendekManaging Director, Head Healthcare Equity Research, Stifel Nicolaus
Michael HayVice President, BioMedTracker Product Manager, Sagient Research Systems
Arlene MorrisCEO, Syndax Pharmaceuticals
David Sable, MDPortfolio Manager, Special Situations Fund
Nathan Tinker, PhDExecutive Director New York Biotechnology Association
-4-
Fireside chats feature candid discussions between biopharma executives and Wall Street analysts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013.
Fireside Chats
Jean-Jacques BienaiméChief Executive Officer BioMarin Pharmaceutical Inc.
N. Anthony ColesChairman & CEO Onyx Pharmaceuticals, Inc.
Robert HuginChairman and Chief Executive Officer Celgene Corporation
John C. Lechleiter, PhDChairman, President and CEO Eli Lilly and Company
John F. Milligan, PhDPresident and Chief Operating Officer, Gilead Sciences, Inc.
-5-
Word on the Street: The Buy-Side View for 2013Monday, February 11th, 12:00pm – 12:55pmPortfolio managers and senior buy-side analysts forecast the year ahead in biotech. This lively panel discussion will be primed with the results of this year’s Investor Perception Study, conducted by BIO’s Industry Analysis Team and ISI Group. Panelists will field a range of questions from valuations and volatility to challenges and opportunities facing institutional investors today.
Moderator:• Mark Schoenebaum, MD, Senior Managing Director and Head, Healthcare Research, ISI Group
Panelists:• Samuel D. Isaly, Managing Partner, OrbiMed Advisors• Oleg Nodelman, Founder & Managing Director, EcoR1 Capital • Nathan Sadeghi-Nejad, Partner, Palkon Capital Management
Tales From the Wild West (Wing): Reflections from White House Chiefs of StaffTuesday, February 12th, 4:00pm – 4:55pmThe election chips have fallen and the country is gearing up for another four years of economic challenges and political wrangling. With divided government, compromises will be difficult and time consuming to reach, but will be necessary to deal with big issues the U.S. faces. Although the fiscal cliff has been averted for now, an unsteady economy and concerns over U.S. debt remain. This session will feature two former White House Chiefs of Staff who have served in the trenches under President Bill Clinton and President George W. Bush. BIO’s CEO and former Congressman, James C. Greenwood, will lead an in depth and lively discussion between Joshua Bolten and John Podesta, who will proffer their views of the political landscape, the outlook for the next four years, the outcome of these key issues and more.
Moderator:• James C. Greenwood, President & CEO, BIO
Panelists:• Joshua Bolten, 22nd White House Chief of Staff • John Podesta, Former White House Chief of Staff and Founder and Chair,
Center for American Progress
Plenary Sessions
James C. Greenwood Joshua Bolten John PodestaMark Schoenebaum Samuel D. Isaly Oleg Nodelman Nathan Sadeghi-Nejad
-6-
Oncology: Panning for Gold—Prospecting the Pancreatic PipelineMonday, February 11th, 10:30am - 11:25amThough pancreatic cancer is the 4th leading cancer malignancy, resulting in nearly 37,000 deaths a year in the US, the pipeline has garnered less attention from industry and the investment community than other oncology indications. There are only two currently approved single agent therapies for this serious disease, but combination treatment regimens are showing tremendous promise yielding a significant increase in overall survival rates. With several phase II and III trials now in the works and positive readouts expected in 2013, the industry is becoming much more intrigued by this potentially underserved space. Hear clinical experts entrenched in the pancreatic cancer late stage treatment pipeline proffer their insights on the future of the disease.
Moderator:• Brian Klein, MD, Vice President & Senior Biotechnology Analyst, Stifel, Nicolaus & Company
Panelists:• John Chabot, MD, FACS, Chief, Division of GI/Endocrine Surgery and Executive Director,
Pancreas Center, New York Presbyterian Hospital/Columbia University • Stewart M. Kroll, Senior Vice President, Clinical Operations and Biostatistics,
Threshold Pharmaceuticals • Peter Laivins, Vice President, Late Stage Drug Development, Merrimack Pharmaceuticals • Mark Miocevich, Global Marketing Lead for Abraxane, Celgene • Kenneth H. Yu, MD, Assistant Professor, Memorial Sloan-Kettering Cancer Center
Therapeutic Workshops
-7-
Orphan Drugs: Making Rare Diseases RarerTuesday, February 12th, 9:00am - 9:55amThe signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug. Some companies have even taken a step beyond and focused primarily on ultra rare disease, potentially providing an even more compelling opportunity. This panel will provide an in-depth analysis of the thriving market opportunity that is rare disease by featuring industry, clinical and regulatory experts specializing in this exciting field.
Moderator:• Ritu S. Baral, Principal, Sr. Analyst- Biotechnology Equity Research, Genuity Partners
Panelists:• Marc Beer, Chief Executive Officer, Aegerion Pharmaceuticals• John F. Crowley, Chairman & CEO, Amicus Therapeutics • Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa • Alvin V. Shih, MD, Chief Operating Officer, Pfizer Rare Disease Research Unit
Oncology: The CLL Chronicles—The Next Chapter in Clinical DevelopmentsTuesday, February 12th, 12:00pm - 12:55pmModerator:
• Joel Sendek, Managing Director & Biotechnology Analyst, Stifel Nicolaus & Company
Panelists:• Jacqueline Barrientos, MD, Assistant Professor of Medicine, Hofstra North Shore-LIJ School of
Medicine CLL Research and Treatment Program • John F. Gerecitano, MD, PhD, Medical Oncologist & Hematologist, Memorial Sloan-Kettering Cancer Center• Kanti Rai, MD, Joel Finkelstein Cancer Foundation Professor of Medicine and Professor of
Molecular Medicine, Hofstra North Shore-LIJ School of Medicine
-8-
Show Me the Money: Reimbursement in an ACA World Monday, February 11, 9:00am - 9:55amWith many key provisions of the Affordable Care Act (ACA) slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Additionally, nearly 30 million more Americans will now have access to health insurance. How will this new environment affect relationships between patients, payors, providers and biopharma companies? How could changes to federal health plans and the creation of state-run insurance exchanges alter biopharma company strategy, from business development to R&D activities? This reimbursement roundtable will feature payors, providers, and other stake-holders from across the industry discussing ACA implementation and the wider reimbursement landscape.
Moderator:• Roger Longman, Chief Executive Officer, Real Endpoints
Panelists:• Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center • Rena Conti, PhD, Assistant Professor of Health Policy & Economics, University of Chicago • Ed Pezalla, MD, MPH, National Medical Director for Pharmacy Policy and Strategy,
Office of the Chief Medical Officer, Aetna • Cynthia Smith, Vice President, Market Access & Commercial Development, Affymax
The Road Less Traveled: Alternative Avenues to Public MarketsTuesday, February 12th, 1:30pm - 2:25pmWhile an IPO has long been a preferred way to go public, an increasing number of companies have employed alternate routes to the public markets, using reverse mergers, Form-10 self-filings, and variations of each to avoid the expense, uncertainty, and complexity of the IPO process. In particular, these alternate avenues may offer advantages by separating the straightforward process of becoming a publicly-filing company from less predictable fund raising. Hear an experienced attorney, executives, and crossover investors who have traveled these new paths discuss lessons learned, deal structures, and how recent legislation like the JOBS Act could affect public exits.
Moderator• William Hicks, Member, Mintz Levin
Panelists:• Charles Crain, Manager, Policy & Research, BIO • Michelle Dipp, MD, PhD, Chief Executive Officer & Co-Founder, OvaScience • Daniel B. Dubin, MD, Vice Chairman, Founder of MEDACorp, Leerink Swann • Peter Kolchinsky, PhD, Managing Partner, RA Capital
Business Roundtables
-9-
Putting a Ring on It—When Drug Development Partnerships Become AcquisitionsTuesday, February 12th, 12:00pm-12:55pmMany recent biopharma acquisitions have started as drug development collaborations including GlaxoSmithKline’s takeover of Human Genome Sciences and Amgen’s purchase of Micromet. How do traditional drug development relationships grow into all-out acquisitions? What business or clinical considerations can prompt the larger company to “take the plunge” and acquire their smaller partner? What deal-breakers should both parties watch for? The panel will feature seasoned business development executives discussing the do’s and don’t’s of taking biopharma collaborations to the next level.
Moderator:• Jeff Stewart, Senior Engagement Manager, Campbell Alliance
Panelists:• Michael Gilman, PhD, Senior Vice President, Early Stage Programs, Biogen Idec• Michael Margolis, RPh, Managing Director, ROTH Capital Partners• Effie Toshav, Partner, Corporate, Fenwick & West LLP
Small Companies Thinking Big—China Tactical StrategiesMonday, February 11th, 3:30pm - 4:25pmBig pharmaceutical companies aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China’s lucrative market and maximize their investment in the country. With more limited resources than multinational biopharma companies, how can these smaller companies operate efficiently and give Chinese patients access to their innovative products? What deal making strategies have proven successful? Industry experts and biotech executives will tackle the tough questions surrounding operational tactics in China.
Moderator:• Jimmy Zhang, PhD, MBA, Managing Director, MSD Early Investments – Greater China, Merck & Co., Inc.
Panelists:• Friedhelm Blobel, PhD, President, CEO, & Director, SciClone Pharmaceuticals• Alan Eisenberg, Executive Vice President, Business Development and Emerging Companies Section, BIO• Kewen Jin, Managing Director, Nimbus Innoworks• Laurence Reid, PhD, Senior Vice President, Chief Business Officer, Alnylam Pharmaceuticals
-10-
The 2013 BIO CEO & Investor Conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above $100M, for the first time this meeting will also include a unique track that features up to 25 high-caliber and established private company presentations.
PuBLIC COMPANIESAastrom BiosciencesACADIA PharmaceuticalsAdvanced Cell TechnologyAdocia ADVENTRX PharmaceuticalsAegerionAffymax AgenusAlkermes plcAlnylam PharmaceuticalsAnteo DiagnosticsAnthera PharmaceuticalsAntisense TherapeuticsApricus BiosciencesAradigm Corp.Arena PharmaceuticalsAstex PharmaceuticalsAthersysAtossa Genetics BiodelBioDelivery Sciences InternationalBioLineRx Ltd.Biotie TherapiesCatalyst Pharmaceutical PartnersCEL-SCI CorporationCempra ChemoCentryx Cleveland BioLabsCyclacel PharmaceuticalsCytokineticsCytomedixCytRx CorporationDARA BioSciencesDiaMedicaDURECT CorporationEpiCept CorporationEternity HealthcareExelixis
Furiex PharmaceuticalsGalena BioPharmaGENFITGeoVax LabsGTxHorizon PharmaiCo TherapeuticsIdenix PharmaceuticalsIdera PharmaceuticalsImmunoCellular TherapeuticsImmunoGenImmunovaccineInnovus PharmaInovio PharmaceuticalsIntercept PharmaceuticalsKeryx Biopharmaceuticals Lexicon PharmaceuticalsMDxHealthNanoViricidesNavidea NeoStemNeuralstemNewron Pharmaceuticals S.p.A.NicOx S.A.NovaBay PharmaceuticalsNovavaxNovelos TherapeuticsNPS PharmaceuticalsNymox Pharmaceutical CorporationOculus Innovative Sciences Ohr PharmaceuticalOncoGenex PharmaceuticalsOncolytics BiotechOncoSec Medical Opexa TherapeuticsOragenicsOrexigenOvaScienceOXiGENE
Oxygen BiotherapeuticsPalatin Technologies PDL BioPharmaPozenPrima Biomed ProMetic Life Sciences Protalix BioTherapeutics Provectus PharmaceuticalspSiVida Corp.Q Therapeutics Regulus TherapeuticsReNeuronRepros TherapeuticsResverlogix Corp.RetrophinRigel PharmaceuticalsRXi PharmaceuticalsSciClone Pharmaceuticals SoligenixStallergenesStemCellsSucampo PharmaceuticalsSynergy PharmaceuticalsSynthetic BiologicsTargacept Tekmira Pharmaceuticals Corp.TengionTG TherapeuticsTiGenix N.V.Tonix PharmaceuticalsTranscept PharmaceuticalsTransition TherapeuticsTranzymeTVAX BiomedicalVenaxis VerastemVirtualScopicsZalicus Zealand Pharma A\SZIOPHARM Oncology
PRIVATE COMPANIESActinium Pharmaceuticals ALS Therapy Development InstituteAratana TherapeuticsCatabasis PharmaceuticalsCoLucid PharmaceuticalsFate TherapeuticsFive Prime TherapeuticsFORMA TherapeuticsGlobeImmuneGood Start GeneticsHydra BiosciencesImmune Design Corp.KaloBios PharmaceuticalsKineMedKinex PharmaceuticalsLeukemia & Lymphoma SocietyMelanoma Research AllianceMersana TherapeuticsMirna TherapeuticsOnconova TherapeuticsPolynomaPromediorProsensa TherapeuticsProteon TherapeuticsRegado BiosciencesSutro BiopharmaSyndax PharmaceuticalsThe Michael J. Fox FoundationTobira TherapeuticsTrevenauniQureZafgen
* As of 01/23/2013
Presenting Companies*
Sign up now to present. Email Sondra Behan at [email protected] or call (866) 356-5155 for more information.
Presenting Companies
-11-
ACAP International, Inc.Acers BioMedicalActin BiomedAegis Capital Corp.Aisling CapitalAkana CapitalAmerican CapitalAmerican PortfoliosApis CapitalApposite CapitalArthritis FoundationAscendiant Capital Markets LLCAspire CapitalATEL VenturesAthyrium CapitalAtika CapitalAtlantic Capital GroupAtlantis InvestmentAtlas VentureAuriga Capital ManagementAvior CapitalBank of America Merrill LynchBarclaysBawcapBaxter Healthcare CorporationBC CapitalBDC Venture CapitalBearing Circle Capital, LPBioRevolution Capital, LLCBioYieldsBlack DiamondBlackRockBloom Burton & Co.Boodell & CompanyBrean Capital, LLCBrinson Patrick SecuritiesBurrage CapitalBurrill SecuritiesBVF Partners LPCantor FitzgeraldCapital Royalty LPCarr SecuritiesCato BioVenturesCeltic Therapeutics Management LPCentreStone VenturesCharlestown Capital Advisors LLCChina Focus LimitedChina Private Equity GroupCitigroupColumbia UniversityCrede Capital Group, LLCCritical Mass PartnersCross Current Research LLCDABAR Investment AssociatesDawson James SecuritiesEaston CapitalEcoR1 CapitalEdgewood Management LLC
Edison Investment ResearchEmerald AdvisersEmergent Rx LLCEminent Venture Capital CorporationEssex Investment Management Company, LLCF.Hoffmann-La Roche LtdFavus Institutional Research LLCFederated Kaufmann FundFidelity InvestmentsFireRock CapitalFountain Healthcare PartnersGagnon SecuritiesGem PartnersGeorge Weiss AssociatesGlobal Corporate Finance ste.Global Energy Capital LLCGolden Seeds LLCGoldman SachsGreen ArrowGreenwich LifeSciencesGriffin SecuritiesGRT CapitalH.I.G. BioVenturesHBM Partners AGHermes Fund ManagersHMCHorizon Technology FinnaceHutchin Hill CapitalIliad Ventures, LLCIngalls & SnyderInnotrove LLCISI Group LLCIssaquena TrustJAIVCJefferies & CompanyJina Ventures Inc.JMP SecuritiesKaminski PartnersKatz AssociatesKearny Venture PartnersKingsbridgeKnoll Capital ManagementKnott Partners, LPLadenburg ThalmannLaidlaw & CompanyLandmark Angels, Inc.Lazard Asset ManagementLedgemont Capital GroupLeviathan Biopharma GroupLifeScience Equity Partners, LLCLifeTech CapitalLincoln Park CapitalLittle Gem Life Sciences FundLoeb PartnersLSWorksMansa CapitalMaryland Biotechnology Center
Maryland Department of Business and Economic DevelopmentMaz Capital AdvisorsMedical StrategyMedimmune Ventures, Inc.Medpro Investors LLCMehta Partners LLCMerck & Co., IncMercury FundMillennium Management LLCMillennium Partners Green ArrowMLV & CoMorgan StanleyMorgens Waterfall VintiadisMP Healthcare Venture ManagementMSMB Capital ManagementMuse CapitalMVP Capital PartnerNeedham & Co.New Leaf Venture PartnersNextech Invest Ltd.Nordcon CapitalNowak Ventures, LLCOppenheimer & Co.Opus Point PartnersOracle PartnersOrbiMed AdvisorsOxford Finance LLCPacific Rim VenturesPadus HealthcarePaisley and Habermas, IncPalkon Capital ManagementPappas VenturesParagon Capital AdvisorsPerceptive AdvisorsPinnacle AssociatesPiper Jaffray & CoPK Healthcare PartnersPOSCO BioVentures FundProfit InvestmentsPW PartnersQuestrion ResearchQuogue Capital LLCQVT FinancialRBC Capital MarketsRevach FundRobert W. BairdRoberts MitaniROTH Capital PartnersRoundbox PartnersRoy Healthcare ResearchRRCMRTW InvestmentsS&P Capital IQSAC CapitalSamtheo Biopharma LLCSendMed Capital
Serrado CapitalSherbrook Capital Management, LLCSigma Capital ManagementSimRxSio Capital ManagementSkyline VenturesSmall Business Technology Investment FundSofinnova VenturesSophrosyne CapitalSpecial Situations FundSpencer Edwards Investment Inc.Spencer TraskStanphyl CapitalStifel NicolausStrategy Signal, LLCSummer Street Research PartnersSunTrust Robinson HumphreySurveyor CapitalSuvretta CapitalSymmetry CapitalSymphony Capital LLCSyzygy TherapeuticsTech Coast AngelsTechnological & Investment HorizonsTerrapin Opportunity FundThe Astrologers Fund, Inc.The Channel GroupThe Invus GroupThe Jordan Family OfficeThe Keiser FoundationThe Livingston GroupThe R. H. Barsom Company IncThird PointThomas, McNerney & PartnersThree Arch PartnersTrellus ManagementTriCygnet LLCTryphon CapitalUBSU.S. Steel Pension FundValence Life SciencesVan Leeuwenhoeck InstituteVenBioVenrockVentures West CapitalVeziris VenturesViscogliosi Brothers, LLCVisium Asset ManagementWBB Securities LLCWK MAHON & CO.World Tech Ventures, LLCWP StewartYorkville Advisors, LLCYoung Capital Partners
*As of 01/25/2013
Participating Investors*
Participating Investors
0
300
600
900
1200
1500
2009 2010 2011 2012
Tota
l Sch
edul
ed M
eetin
gs
One-on-One Partnering Statistics
-12-
BIO One-on-One Partnering is proprietary software developed by BIO that allows selected registrants to utilize an online database tool to:
• Pre-schedule 30-minute private 1x1 meetings • Source potential collaborations and funding opportunities with an international audience • Communicate directly with prospective investors and senior management in biotech and pharma • Search company and investor profiles
One-on-One Meetings
Over 1,300 scheduled meetings in 2012
60% growth in scheduled meetings since 2009
Company & Company 9%
Investor & Investor 3%
Company & Investor 88%
Rare/Genetic Diseases: 3%
Oncology 27%
CNS 16%
Other 10%
Infectious Diseases: 7%
Autoimmune/Inflammation
5%
Metabolic 5%
Cell Therapy/Regenerative Medicine: 5%
Platform/ Discovery: 4%
Cardiovascular 4%
Gastrointestinal Disorders: 4%
Ophthalmology 4%
Vaccines: 4%Diagnostics
3%
Therapeutic Focus
Market Cap
500M-1B 7%
250-500M 11%
100-250M 19%50-100M
29%
<50M 27%
>$1B: 6%
-13-
300+ companies
Nearly 600 investors
-14-
Agenda*
Monday,February 11, 2013
Conrad Duke of Windsor Park South Basildon East Foyer Jade/Astor
4th Floor 3rd Floor7:00 – 7:55am Networking Breakfast: Grand Ballroom8:00 – 8:45am Fireside Chat with Robert Hugin, Chairman and CEO, Celgene Corporation (Astor)
9:00 – 9:25am Galena BioPharma
Oxygen Biotherapeutics
Proteon TherapeuticsGTx TBD Show Me
the Money: Reimbursement in an ACA World
(Jade)
Tobira Therapeutics
9:30 – 9:55am Verastem Transition Therapeutics
Regado Biosciences Oncolytics Biotech ChemoCentryx
ALS TDI (PAG)
10:00 – 10:25am Advanced Cell Technology DiaMedica
CoLucid Pharmaceuticals ImmunoCellular
TherapeuticsRigel
PharmaceuticalsActinium Pharmaceuticals
10:30 – 10:55am ReNeuron GENFITOnconova Therapeutics Furiex
PharmaceuticalsNPS
PharmaceuticalsOncology:
Panning for Gold—Prospecting
the Pancreatic Pipeline (Jade)
uniQure
11:00 – 11:25am Palatin Technologies CEL-SCI Corporation
Fate Therapeutics Repros Therapeutics
Lexicon PharmaceuticalsZafgen
11:30 – 11:55am NovaBay Pharmaceuticals
Provectus Pharmaceuticals
LL Society (PAG)TONIX
Pharmaceuticals TBDFive Prime Therapeutics
12:00 – 12:55pm Openingg Plenary Session: Word on the Street – Buy-Side View for 2013 (Jade) – Box Lunch
1:00 – 1:25pm Anteo Diagnostics Atossa Genetics
Catabasis Pharmaceuticals
Targacept TBD
Fireside Chat with John
Lechleiter, PhD, Chairman,
President and CEO, Eli Lilly
(Astor, 1:00-1:45pm)
Promedior
1:30 – 1:55pm ProMetic Life Sciences CytRx Corporation
KineMedBiotie Therapies Synergy
PharmaceuticalsRib-X Pharmaceuticals
2:00 – 2:25pm NeoStem Novelos Therapeutics Good Start Genetics Cleveland BioLabs
Zealand Pharma A/S Biosimilars:
Beyond the New Pathway for
Approval (Jade)2:30 – 2:55pm Opexa Therapeutics VirtualScopics TBD Cyclacel
Pharmaceuticals
Keryx Biopharma-
ceuticals
3:00 – 3:25pm Idera Pharmaceuticals Biodel Oculus Innovative
Sciences MDxHealth Novavax
3:30 – 3:55pm Q Therapeutics Eternity Healthcare Antisense Therapeutics TG Therapeutics Navidea Small Companies
Thinking Big: China Tactical
Strategies(Jade)
4:00 – 4:25pmCatalyst
Pharmaceutical Partners
RXi Pharmaceuticals Venaxis Anthera Pharmaceuticals Stallergenes
4:30 – 4:55pm Cytomedix Ohr Pharmaceutical Tranzyme Horizon Pharma
Intercept Pharmaceuticals
5:00 – 6:30pm BIO CEO Reception (Empire Room)
* As of 1/23. Program schedule subject to change. Please go to www.bio.org/bioceo or visit us onsite for updates.
-15-
Tuesday,February 12, 2013
Conrad Duke of Windsor Park South Basildon East Foyer Jade/Astor4th Floor 3rd Floor
7:00 – 7:40am Networking Breakfast (Grand Ballroom)
7:45 – 8:25am Fireside Chat with N. Anthony Coles, MD, Chairman & CEO, Onyx Pharmaceuticals (Astor)
8:30 – 8:55am TiGenix N.V. StemCellsPolynoma
OvaScience ExelixisTrevena
9:00 – 9:25am Athersys ZalicusSutro Biopharma
Resverlogix Corp. ImmunoGen Orphan Drugs:
Making Rare Diseases Rarer
(Jade)
Syndax Pharmaceuticals
9:30 – 9:55am Inovio Pharmaceuticals Neuralstem
GlobeImmune
Cempra AffymaxAratana Therapeutics
10:00 – 10:25am Apricus Biosciences
ADVENTRX Pharmaceuticals
Immune Design Corp.
Agenus ACADIA PharmaceuticalsFORMA
Therapeutics
10:30 – 10:55amTekmira
Pharmaceuticals Corp.
Tengion
Mersana Therapeutics Nymox
Pharmaceutical Corporation
ZIOPHARM OncologyKinex
Pharmaceuticals
11:00 – 11:25am Synthetic Biologics DURECT Corporation
MJFF (PAG)
TBD TBD
Fireside Chat with John Milligan, PhD,
President and COO, Gilead Sciences (Astor)
Hydra Biosciences
11:30 – 11:55am NanoViricides Prima Biomed Ltd.
Prosensa Therapeutics Astex
PharmaceuticalsProtalix
BioTherapeuticsKaloBios Pharmaceuticals
12:00 – 12:55pm(Box Lunch)
Business Development: Putting a Ring on It—When Drug Development Deals
Turn into Acquisitions (Astor)
Oncology: The CLL Chronicles—
The Next Chapter in Clinical Developments (Jade)
1:00 – 1:25pm OncoGenex Pharmaceuticals Regulus Therapeutics pSiVida Corp. Sucampo
Pharmaceuticals Alkermes plc
1:30 – 1:55pm Oragenics Immunovaccine iCo Therapeutics
BioDelivery Sciences
International
Arena Pharmaceuticals
The Road Less Traveled:
Alternative Avenues to Public Markets
(Jade)2:00 – 2:25pm BioLineRx Ltd. Aradigm Corp. DARA BioSciences
SciClone Pharmaceuticals Orexigen
2:30 – 2:55pm Transcept Pharmaceuticals GeoVax Labs EpiCept
Corporation Cytokinetics Alnylam Pharmaceuticals
3:00 – 3:25pmNewron
Pharmaceuticals S.p.A
Soligenix OncoSec Medical
Aastrom Biosciences
Idenix Pharmaceuticals
3:30 – 3:55pm Pozen Retrophin OXiGENE NicOx S.A. PDL BioPharma
Fireside Chat with JJ Bienaimé
CEO, BioMarin (Astor)
4:00 – 4:55pm Closing Plenary: Tales From the Wild West (Wing): Reflections from White House Chiefs of Staff (Jade)
5:00 – 6:00pm Closing Happy Hour (Silver Corridor)
Conference Size 1,150+
One-on-One PartneringTM Meetings 1,300+
Investors Attending 600
Company Presentations 140
Audience Profile
-16-
Who Should Attend?
Associate 10% Other
7%
Executive 36%Manager
10%
V.P. 11%
Analyst 11%
Director 15%
Attendees by Title
Over 1,100 attendees from 16 different countries
Over 35% of attendees are executives
-17-
BIO offers a number of ways for conference attendees to save money on their registration fees.
Discounted packages for presenting companies bringing three or more attendees.
Special rates for academics and service providers.
Complimentary registration is available to qualified institutional (buy and sell-side), private equity, and venture investors.
Go to bio.org/bioceo/register and register now.
Join the conversation:Learn more about Biotechnology at bio.orgEngage with the Biotech Community at BIOtech-NOW.orgFollow us on Twitter @bio1x1 or #BIOCEO13Become a fan on Facebook (facebook.com/IAmBiotech)
Academic Service Providers InvestorsPublic Company Private Company-New! Public Company Private Company-New! Additional Attendee Registration Fee Registration Fee Registration Fee
Early Rate$5,785 members$8,295 non-members
$4,795 members$7,095 non-members
$1,495 members$2,195 non-members
$1,495 members $2,195 non-members
$1,095 members $1,695 non-members
$895 members $895 non-members
$3,195 members $4,195 non-members Complimentary
Late Rate$6,396 members$9,295 non-members
$5,395 members$8,095 non-members
$1,895 members$2,895 non-members
$1,895 members $2,895 non-members
$1,395 members $2,895 non-members
$895 members $895 non-members
$4,195 members $5,195 non-members Complimentary
Presentation
Additional rate:$2,895 members $3,795 non-members
Additional rate: $1,895 members $2,595 non-members
Presenter Registration
Early additional attendee:$1,095 members$1,695 non-members
Early additional attendee:$1,095 members$1,695 non-members
Late additional attendee:$1,395 members$2,895 non-members
Late additional attendee:$1,395 members$2,895 non-members
1x1 PartneringOpening ReceptionNetworking BreakfastsAttend Company PresentationsProgramming Panels
Early Member Rate Total:
3 people with presentation: $5,785
3 people with presentation: $4,795
1 person with presentation: $4,390
1 person with presentation: $3,390
2 people with presentation:Public- $5,785 Private- $3,485
Early Non- 2 people with presentation:
Group Package: 3+ People Individual Packages: 1-2 people
2 additional registrations
Member Rate Total:
3 people with presentation: $8,295
3 people with presentation: $7,095
1 person with presentation: $5,990
1 person with presentation: $4,790
Public- $7,685 Private- $6,485
Book now and save 10%!
Reserve your space today!
3
3
3
SponsorsSupporting Bank Sponsors
BIO Double Helix Sponsors BIO Helix Sponsors
Conference Supporters
Media Partners
Local Co-Host
Contact us today for a tailored sponsorship package to meet your business objectives. Contact Matt Lowe at [email protected] or call 202.312.9277. For more information on BIO sponsorships, please visit www.bio.org/sponsor
Member FINRA/SIPC